These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27134662)

  • 1. Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.
    Jahnsen J
    Therap Adv Gastroenterol; 2016 May; 9(3):322-9. PubMed ID: 27134662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J; Kaasen Jørgensen K
    Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
    Parigi TL; D'Amico F; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2021 Jan; 21(1):37-46. PubMed ID: 32799561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world data on the infliximab biosimilar CT-P13 (Remsima
    Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM
    World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease.
    Albshesh A; Ben-Horin S
    Expert Opin Biol Ther; 2019 Oct; 19(10):971-978. PubMed ID: 31401899
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of biosimilars in the treatment of inflammatory bowel diseases.
    Park DI
    Intest Res; 2016 Jan; 14(1):15-20. PubMed ID: 26884730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease.
    Kashima S; Sawada K; Moriichi K; Fujiya M
    Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
    Sagami S; Nishikawa K; Yamada F; Suzuki Y; Watanabe M; Hibi T
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2091-2100. PubMed ID: 33450057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
    Danese S; Fiorino G
    Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous Infliximab, CT-P13 SC: A Profile of Its Use in the EU.
    Shirley M
    Clin Drug Investig; 2021 Dec; 41(12):1099-1107. PubMed ID: 34727347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME; Vulto A; de Ridder L
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.